BD (Becton, Dickinson and Company) has launched a new patient-safety program for hospitals, called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME). Aimed at addressing the two critical challenges in a hospital setting – infection prevention and medication safety – PRIME is developed by Joint Commission International (JCI) for patient safety, with sponsorship by BD.
A unique programmatic approach toward patient safety will be implemented over a six-month duration, composed of goal-setting, constant progress review, tele-consultations with experts, and scientific updates through webinars. Hospitals will be certified upon successful completion of the program. So far, the hospitals that have signed up for the program in India are: Kolkata – Belle Vue Clinic, Fortis Hospital Anandapur; Mumbai – Breach Candy, Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Trivandrum – Kerala Institute of Medical Sciences; Manipal – Kasturba Hospital; Mohali – Fortis Hospital; Delhi/NCR – Max Healthcare, Saket, and Medanta The Medicity-Gurgaon. PRIME has been launched across South Korea, Japan, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and India.
BD-India & South Asia
“Increasingly, healthcare facilities across India are working to upgrade quality standards to achieve a future of better patient outcomes, increased patient safety and cost efficiency in healthcare systems. In this pursuit of quality and safety, BD is pleased to work on enabling the hospitals achieve standardized and compliant care and improve patient outcomes through PRIME – a gold-standard benchmarked safety program with JCI. Through this hallmark program for hospitals, BD will be able to help enhance patient and clinical outcomes by eliminating complications and improving safety for patients and providers leading to accessing better care.”